Peringatan Keamanan

Data regarding overdose of leronlimab is not readily available.

Leronlimab

DB05941

biotech investigational

Deskripsi

Leronlimab, or PRO-140, is a human monoclonal antibody developed by CytoDyn.L12684 It was first described in the literature in 2001.A3922 This antibody binds to CCR5, which may be useful in treating HIV, cancers, and severely ill COVID-19 patients.A192846,A192858,L12684

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The half life of a 162mg subcutaneous dose is 3.4 days while the half life of a 324mg subcutaneous dose is 3.7 days.[A192846]
Volume Distribusi Data regarding the volume of distribution of leronlimab is not readily available.
Klirens (Clearance) Data regarding the clearance of leronlimab is not readily available.

Absorpsi

A 162mg subcutaneous dose reaches a Cmax of 6.1mg/L, with a Tmax of 32 hours, and an AUC of 24.4mg\*day/L.A192846 A 324mg subcutaneous dose reaches a Cmax of 13.8mg/L, with a Tmax of 56 hours, and an AUC of 58.8mg\*day/L.A192846

Metabolisme

Data regarding the metabolism of leronlimab is not readily available. However, as a monoclonal antibody it is expected to be degraded to smaller proteins and amino acids by proteolytic enzymes.

Rute Eliminasi

Data regarding the route of elimination of leronlimab is not readily available.

Interaksi Obat

387 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Leronlimab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Leronlimab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Leronlimab.
Estrone Estrone may increase the thrombogenic activities of Leronlimab.
Estradiol Estradiol may increase the thrombogenic activities of Leronlimab.
Dienestrol Dienestrol may increase the thrombogenic activities of Leronlimab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Leronlimab.
Mestranol Mestranol may increase the thrombogenic activities of Leronlimab.
Estriol Estriol may increase the thrombogenic activities of Leronlimab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Leronlimab.
Quinestrol Quinestrol may increase the thrombogenic activities of Leronlimab.
Hexestrol Hexestrol may increase the thrombogenic activities of Leronlimab.
Tibolone Tibolone may increase the thrombogenic activities of Leronlimab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Leronlimab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Leronlimab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Leronlimab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Leronlimab.
Zeranol Zeranol may increase the thrombogenic activities of Leronlimab.
Equol Equol may increase the thrombogenic activities of Leronlimab.
Promestriene Promestriene may increase the thrombogenic activities of Leronlimab.
Methallenestril Methallenestril may increase the thrombogenic activities of Leronlimab.
Epimestrol Epimestrol may increase the thrombogenic activities of Leronlimab.
Moxestrol Moxestrol may increase the thrombogenic activities of Leronlimab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Leronlimab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Leronlimab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Leronlimab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Leronlimab.
Biochanin A Biochanin A may increase the thrombogenic activities of Leronlimab.
Formononetin Formononetin may increase the thrombogenic activities of Leronlimab.
Estetrol Estetrol may increase the thrombogenic activities of Leronlimab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Leronlimab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Leronlimab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Leronlimab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Leronlimab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Leronlimab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Leronlimab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Leronlimab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Leronlimab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Leronlimab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Leronlimab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Leronlimab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Leronlimab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Leronlimab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Leronlimab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Leronlimab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Leronlimab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Leronlimab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Leronlimab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Leronlimab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Leronlimab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Leronlimab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Leronlimab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Leronlimab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Leronlimab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Leronlimab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Leronlimab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Leronlimab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Leronlimab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Leronlimab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Leronlimab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Leronlimab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Leronlimab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Leronlimab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Leronlimab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Leronlimab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Leronlimab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Leronlimab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Leronlimab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Leronlimab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Leronlimab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Leronlimab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Leronlimab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Leronlimab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Leronlimab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Leronlimab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Leronlimab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Leronlimab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Leronlimab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Leronlimab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Leronlimab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Leronlimab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Leronlimab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Leronlimab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Leronlimab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Leronlimab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Leronlimab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Leronlimab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Leronlimab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Leronlimab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Leronlimab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Leronlimab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Leronlimab is combined with Glembatumumab vedotin.
Olaratumab The risk or severity of adverse effects can be increased when Leronlimab is combined with Olaratumab.
IPH 2101 The risk or severity of adverse effects can be increased when Leronlimab is combined with IPH 2101.
TB-402 The risk or severity of adverse effects can be increased when Leronlimab is combined with TB-402.
Caplacizumab The risk or severity of adverse effects can be increased when Leronlimab is combined with Caplacizumab.
IMC-1C11 The risk or severity of adverse effects can be increased when Leronlimab is combined with IMC-1C11.
Eldelumab The risk or severity of adverse effects can be increased when Leronlimab is combined with Eldelumab.
Lumiliximab The risk or severity of adverse effects can be increased when Leronlimab is combined with Lumiliximab.
Canakinumab The risk or severity of adverse effects can be increased when Leronlimab is combined with Canakinumab.

Target Protein

C-C chemokine receptor type 5 CCR5

Referensi & Sumber

Artikel (PubMed)
  • PMID: 11134270
    Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, Moore JP, Maddon PJ, Olson WC: Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol. 2001 Jan;75(2):579-88.
  • PMID: 20377413
    Jacobson JM, Thompson MA, Lalezari JP, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC: Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J Infect Dis. 2010 May 15;201(10):1481-7. doi: 10.1086/652190.
  • PMID: 31747383
    Kranjc MK, Novak M, Pestell RG, Lah TT: Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme. Radiol Oncol. 2019 Nov 20;53(4):397-406. doi: 10.2478/raon-2019-0057.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul